Fludarabine in chronic leukaemia
- 1 May 1996
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 347 (9013) , 1420-1421
- https://doi.org/10.1016/s0140-6736(96)91675-x
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1995
- Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders [published erratum appears in Blood 1996 Mar 1;87(5):2093]Blood, 1995
- Infectious and immunosuppressive complications of purine analog therapy.Journal of Clinical Oncology, 1995
- Advances in the biology and treatment of B-cell chronic lymphocytic leukemiaBlood, 1995
- Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]Blood, 1993
- Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.Journal of Clinical Oncology, 1991
- Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.Journal of Clinical Oncology, 1991
- Fludarabine: a new agent with major activity against chronic lymphocytic leukemiaBlood, 1989